Answers are grounded in this paper and cite their sources.
Abstract Reprogramming of lipid metabolism is a new mark of malignancy. Sterol Regulatory Element-Binding Transcription Factor 1 (SREBF1) plays a central role in lipid metabolism, but has rarely been reported. This study aimed to analyze the expression, prognosis and immunological significance of SREBF1 in pan-cancer. SREBF1 expression profiles were obtained from The Cancer Genome Atlas (TCGA), Genotype-Tissue Expression (GTEx) and Cancer Cell Line Encyclopedia (CCLE) databases. Area under the ROC curve, Cox regression and Kaplan-Meier analysis were performed to assess the clinical diagnostic and prognostic value of SREBF1. Subsequently, its biological functions and its correlations with tumor microenvironment (TME), chemokines, immune checkpoints, immune cell infiltration, immune stimulator, immune inhibitors, mismatch repair (MMR), tumor mutational burden (TMB) and microsatellite instability (MSI) were assessed, and mRNA-miRNA-lncRNA network was constructed. SREBF1 was found to be highly expressed in 15 cancers, had diagnostic value in 24 cancers, and was an independent key factor in the prognosis of multiple cancers. Moreover, SREBF1 significantly correlated with TME and immune-related functions in multiple cancers, and was mainly involved in metabolism- and immune-related functions. Finally, we provided many lncRNA and miRNA targets regulating SREBF1. Taken above, our study highlights SREBF1 as a promising prognostic and immunological biomarker in pan-cancer.
No takes yet. Share an insight, caveat, or question.
Zhang et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: